Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Active, not recruiting · NCT03190278 · Registry updated 2025-08-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 | 2025-08-07 | NCT03190278 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cellectis S.A. | 3 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa | United States | 13 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Northwestern University | Chicago | United States | 3 |
| Roswell Park Cancer Institute | Buffalo | United States | 382 |
| University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center | San Francisco | United States | 1 |
| University of Pennsylvania - Abramson Cancer Center | Philadelphia | United States | 6 |
| Weill Medical College of Cornell University | New York | United States | 9 |